User profiles for Lucia Baratto

Lucia Baratto

MD, Clinical Research Scientist Stanford University
Verified email at stanford.edu
Cited by 1081

Predicting response to immunotherapy by evaluating tumors, lymphoid cell-rich organs, and immune-related adverse events using FDG-PET/CT

T Nobashi, L Baratto, SA Reddy, S Srinivas… - Clinical nuclear …, 2019 - journals.lww.com
Purpose To investigate whether the evaluation of tumors, lymphoid cell-rich organs, and
immune-related adverse events (IRAE) with 18 F-FDG PET/CT can predict the efficacy and …

[HTML][HTML] Evaluation of integrin αvβ6 cystine knot PET tracers to detect cancer and idiopathic pulmonary fibrosis

…, T Haywood, L Abou-Elkacem, L Baratto… - Nature …, 2019 - nature.com
Advances in precision molecular imaging promise to transform our ability to detect, diagnose
and treat disease. Here, we describe the engineering and validation of a new cystine knot …

Artificial intelligence enables whole-body positron emission tomography scans with minimal radiation exposure

YR Wang, L Baratto, KE Hawk, AJ Theruvath… - European journal of …, 2021 - Springer
Purpose To generate diagnostic 18 F-FDG PET images of pediatric cancer patients from
ultra-low-dose 18 F-FDG PET input images, using a novel artificial intelligence (AI) algorithm. …

Prostate cancer theranostics targeting gastrin-releasing peptide receptors

L Baratto, H Jadvar, A Iagaru - Molecular imaging and biology, 2018 - Springer
Gastrin-releasing peptide receptors (GRPRs), part of the bombesin (BBN) family, are aberrantly
overexpressed in many cancers, including those of the breast, prostate, pancreas, and …

[HTML][HTML] End-of-treatment and serial PET imaging in primary mediastinal B-cell lymphoma following dose-adjusted EPOCH-R: a paradigm shift in clinical decision …

…, M Roschewski, KM Walters, CC Chen, L Baratto… - …, 2018 - ncbi.nlm.nih.gov
Dose-adjusted-EPOCH-R obviates the need for radiotherapy in most patients with primary
mediastinal B-cell lymphoma. End-of-treatment PET, however, does not accurately identify …

PSMA-and GRPR-targeted PET: results from 50 patients with biochemically recurrent prostate cancer

L Baratto, H Song, H Duan, N Hatami… - Journal of Nuclear …, 2021 - Soc Nuclear Med
Novel radiopharmaceuticals for PET are being evaluated for the diagnosis of biochemical
recurrence (BCR) of prostate cancer (PC). We compared the gastrin-releasing peptide receptor…

[HTML][HTML] 18F-FDG silicon photomultiplier PET/CT: A pilot study comparing semi-quantitative measurements with standard PET/CT

L Baratto, SY Park, N Hatami, G Davidzon, S Srinivas… - PloS one, 2017 - journals.plos.org
Purpose To evaluate if the new Discovery Molecular Insights (DMI) PET/CT scanner provides
equivalent results compared to the standard of care PET/CT scanners (GE Discovery 600 …

Imaging the distribution of gastrin-releasing peptide receptors in cancer

L Baratto, H Duan, H Mäcke… - Journal of Nuclear …, 2020 - Soc Nuclear Med
Targeting tumor-expressed receptors using selective molecules for diagnostic, therapeutic,
or both diagnostic and therapeutic (theragnostic) purposes is a promising approach in …

[HTML][HTML] Initial experience with a SiPM-based PET/CT scanner: influence of acquisition time on image quality

I Sonni, L Baratto, S Park, N Hatami, S Srinivas… - EJNMMI physics, 2018 - Springer
Background A newly introduced PET/CT scanner (Discovery Meaningful Insights—DMI, GE
Healthcare) includes the silicon photomultiplier (SiPM) with time-of-flight (TOF) technology …

Prognostic value of somatostatin receptor expressing tumor volume calculated from 68Ga-DOTATATE PET/CT in patients with well-differentiated neuroendocrine …

A Toriihara, L Baratto, T Nobashi, S Park… - European journal of …, 2019 - Springer
Purpose To evaluate the prognostic value of volumetric parameters calculated from 68 Ga-1,4,7,10-tetraazacyclododecane-1,
4, 7, 10-tetraacetic acid (DOTA)-Thr 3 -octreotate ( 68 Ga-…